The 29th JFCR－ISCC
December 10-11, 2025
Miraikan - The National Museum of Emerging Science and Innovation 7F
2-3-6, Aomi, Koto-ku, Tokyo, Japan
December 10
12:00-12:30
Committee meeting
Opening Remark
12:50-13:00
Naoya Fujita (Cancer Chemotherapy Center, JFCR)
Opening remark
Session I: Antibody therapeutics: Targeting to functional design
Chairpersons: Yves Pommier (National Cancer Institute, NIH, Bethesda, MD, USA),
Atsushi Ohtsu ( JFCR, Tokyo)
13:00-13:30
Yosuke Yoshida (Daiichi Sankyo Co., Ltd., Tokyo)
Clinical development of R-DXd, a novel CDH6-targeting DXd-ADC
13:30-14:00
Hiroki Hayashi (Chugai Pharmaceutical Co., Ltd., Kanagawa)
ROSE12, A Novel ATP-dependent FcγRs affinity-enhanced anti-CTLA-4 switch antibody for tumour-selective enhancement of anti-tumour immunity
14:00-14:10
Discussion
Meet-the-Expert 1
Chairperson: Hiromichi Ebi (Aichi Cancer Center Research Institute, Aichi)
14:10-14:50
Ryan Corcoran (Mass General Brigham Cancer Institute, MGH, Boston, MA, USA)
Combination strategies to increase the efficacy of KRAS inhibition
14:50-15:00
Discussion
15:00-15:20
Coffee Break
Session II: Targeting RAS-driven cancers
Chairpersons: Ryan Corcoran (Mass General Brigham Cancer Institute, MGH, Boston, MA, USA),
Shunji Takahashi (Cancer Institute Hospital, JFCR, Tokyo)
15:20-15:50
Hiromichi Ebi (Aichi Cancer Center Research Institute, Aichi)
KRAS-mutant cancers: Current landscape and emerging therapies
15:50-16:30
TBD
16:30-17:00
Pankaj Punia (Astellas Pharma Oncology Development, Addlestone, UK)
Development spotlight: Advancing KRAS-targeted therapies through ASP5834 and ASP3082
17:00-17:10
Discussion
Poster Flash talk
Chairperson: Manabu Kawada (Institute of Microbial Chemistry, Tokyo)
17:10-17:55
Masahiro Esaki (Kyowa Kirin Co., Ltd.)
Efficacy of novel BET degrader K-256 in MYC/BCL2-related lymphoma
Noritaka Tanaka (Aichi Cancer Center Research Institute)
Overcoming intrinsic resistance to combinational therapy of KRAS and immune checkpoint inhibitor with the additional inhibition of CD47
Wang Yihan (The Univeristy of Tokyo)
Rational design of frontline combination therapies involving KRAS G12D inhibitors for KRAS G12D-mutant tumors
Kanako Iguchi (Astellas Pharma Inc.)
Non-clinical study of ASP4396, a novel KRAS G12D degrader, shows remarkable anti-tumor activity in KRAS G12D mutant cancer models
Masaru Yokomura (Cancer Chemotherapy Center, JFCR)
Discovery of cancer immunotherapy resistance driven by loss-of-function mutation of ubiquitin ligase component
Hirokazu Kusunoki (Kanazawa University)
One-carbon metabolic enzyme MTHFD1L contributes to tumorigenesis and lung metastasis
Mingrui Jiang (EPOC, National Cancer Center)
Chondroitin sulfate remodeling drives gastric cancer progression by modulating tumor microenvironment
Yoshiki Nonaka (Osaka Metropolitan University)
Spatial autocorrelation analysis reveals immunosuppressive zone at the liver tumor margin
Chiaki Kobayashi (Kyowa Kirin Co., Ltd.)
The novel and potent CD40 agonist KHK2840
Toshiya Machida (MSD K.K.)
A phase 1b/2 study of gocatamig and ifinatamab deruxtecan for relapsed or refractory extensive-stage small cell lung cancer
Sho Isoyama (Cancer Chemotherapy Center, JFCR)
EWSR1: FLI1 drives immune evasion in Ewing's sarcoma by utilizing regulatory T cells to suppress NK cells
Ryo Sawada (Kyoto Prefectural University of Medicine)
Application of reprogramming technology for drug development targeting osteosarcomas
Poster viewing and networking
17:55-19:10
December 11
Session III: Mapping cancer at single-cell resolution
Chairpersons: Liron Bar-Peled (Massachusetts General Hostpital, Boston, MA, USA),
Naoko Ohtani (Osaka Metoropolitan University, Osaka)
9:00-9:40
Ignacio Vazquez-Garcia (MGH, Harvard Medical School, Boston, MA, USA)
Tracing cancer dynamics at single-cell resolution
9:40-10:20
Sydney M. Shaffer (University of Pennsylvania, Philadelphia PA, USA)
Tracking and targeting dynamic cell states in therapy resistance
10:20-10:50
Ayako Suzuki (The University of Tokyo, Tokyo)
Elucidating aberrant tumor cell and microenvironment status in spatial and single-cell omics analysis
10:50-11:00
Discussion
11:00-11:20
Coffee Break
Meet-the-Expert 2
Chairperson: Hiroyuki Seimiya (Cancer Chemotherapy Center, JFCR, Tokyo)
11:20-12:00
Liron Bar-Peled (MGH Cancer Institute, Harvard Medical School, Boston, MA, USA)
An ‘Omics approach to drug discovery
12:00-12:10
Discussion
Luncheon Seminar (Supported by Nippon Kayaku)
Chairperson: Takashi Seto (National Hospital Organization Kyushu Cancer Center, Fukuoka)
12:20-13:10
Misako Nagasaka (University of California Irvine School of Medicine , Irvine, CA, USA)
Updates in ROS1-positive NSCLC: Advances in ROS1 inhibitors and strategies against resistance
13:10-13:20
Break
Session IV: Groundbreaking advances in cancer immunotherapy
Chairpersons: Taha Merghoub (Weill Cornell Medicine, New York, NY, USA),
Shigehisa Kitano (Cancer Institute Hospital, JFCR, Tokyo)
13:20-13:50
Yosuke Togashi (Okayama University, Okayama)
Tumor-derived mitochondrial “Hijack” in the tumor microenvironment
13:50-14:20
Keisuke Watanabe (NCC, Tokyo)
Engineering CARs for T-cell malignances and solid tumors
14:20-15:00
Taha Merghoub (Weill Cornell Medicine, New York, NY, USA)
TBD
15:00-15:10
Discussion
15:10-15:30
Coffee Break
Session V: AI & Quantum technologies driven drug development
Chairpersons: Ignacio Vazquez-Garcia (MGH, Harvard Medical School, Boston, MA, USA),
Kentaro Yamamoto (Quantinuum K.K., Tokyo)
15:30-16:00
Kentaro Yamamoto (Quantinuum K.K., Tokyo)
Quantum computing: pushing the boundary of computational chemistry
16:00-16:30
Reiji Teramoto (Chugai Pharmaceutical Co., Ltd., Kanagawa)
Harnessing the power of ML/AI technologies in antibody drug discovery
16:30-16:40
Discussion
Closing Remark
16:40-16:50
Yves Pommier (National Cancer Institute, NIH, Bethesda, MD, USA)
Closing remark